858-449-1310 contact@somatek.com

Biologics

Monoclonal for Alzheimer’s

On Monday FDA approved Biogen’s aducanumab, brand name Aduhelm, through a program called accelerated approval. Aduhelm is the first new medication for Alzheimer’s disease in nearly two decades. FDA’s decision was welcomed by patients and their families as a...

read more

RNA therapeutics

To those developing treatments for oncology, in the gene therapy space and many other fields it seemed for a long time that RNA-based therapies have many attractive properties but somehow just too many obstacles to overcome. Enter recent break-throughs in vaccine...

read more

Somatek looks back at 2020

It goes without saying, 2020 was a year with major challenges and disruptions. However, it was also a year of growth and new opportunities for the biotechnology industry and for Somatek. In the summer of 2020, Somatek moved into newly renovated laboratory facilities...

read more

HAPPY 2021

Somatek wishes all its clients, colleagues, associates and friends a very happy and healthy New Year!!

read more

Cold chain is a hot topic among investors

The Pfizer and BioNTech vaccine against COVID-19 received an emergency use authorization from the FDA last Friday, and thousands of doses are being rolled out across the country this week. But the vaccine, which must be stored at between -80 and -60 degrees Celsius, necessitates the utilization of a “cold chain” to keep it within this temperature range from the moment it leaves the manufacturing site to just before it is administered to a patient.

read more

Tiny bovine antibody fragments show big potential

In the world of monoclonal antibodies, being small is a big deal. Smaller antibodies and antibody fragments can penetrate solid tumors that would be inaccessible to larger antibodies, and some can even make it across the blood-brain barrier. That’s why it’s exciting that researchers at the University of Bath and UCB (a Belgian biotech company) have designed extra-small antibody fragments from cows.

read more

Novel fusion protein could help hemophilia A patients

Hemophilia A, a rare medical condition that prevents blood from clotting properly, may soon have a new therapy to contend with, courtesy of a team led by hematologist Barbara Konkle of Bloodworks Northwest. A new fusion protein based on factor VIII has shown promising results in a small-scale clinical trial and has some researchers hopeful that this novel therapy could make life easier for hemophilia A patients.

read more